A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Glycopyrronium
Eltrombopag
The metabolism of Fusidic acid can be decreased when combined with Eltrombopag.
Glycopyrronium
Deferasirox
The metabolism of Fusidic acid can be decreased when combined with Deferasirox.
Glycopyrronium
Flunitrazepam
The metabolism of Fusidic acid can be decreased when combined with Flunitrazepam.
Glycopyrronium
Gemfibrozil
The metabolism of Fusidic acid can be decreased when combined with Gemfibrozil.
Glycopyrronium
Fenofibric acid
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Fenofibric acid.
Glycopyrronium
Clofibride
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Clofibride.
Glycopyrronium
Aluminium clofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Aluminium clofibrate.
Glycopyrronium
Ronifibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Ronifibrate.
Glycopyrronium
Simfibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Simfibrate.
Glycopyrronium
Emetine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Emetine.
Glycopyrronium
Mebeverine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Mebeverine.
Glycopyrronium
Ubidecarenone
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Ubidecarenone.
Glycopyrronium
Ciprofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Ciprofibrate.
Glycopyrronium
Acipimox
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Acipimox.
Glycopyrronium
Etofibrate
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Etofibrate.
Glycopyrronium
Raltegravir
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Fusidic acid is combined with Raltegravir.
Glycopyrronium
Procarbazine
The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Procarbazine is combined with Fusidic acid.
Glycopyrronium
Clorindione
The risk or severity of bleeding can be increased when Fusidic acid is combined with Clorindione.
Glycopyrronium
Fluindione
The risk or severity of bleeding can be increased when Fusidic acid is combined with Fluindione.
Glycopyrronium
4-hydroxycoumarin
The risk or severity of bleeding can be increased when Fusidic acid is combined with 4-hydroxycoumarin.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3